The Benefits of Genetic Addiction Risk Score (GARS

Area of Science:

• Genetics
• Neuroscience
• Pharmacology

Background:

• The Genetic Addiction Risk Score (GARS) is a panel of ten reward gene risk variants developed over 25 years of research.
• The Addiction Severity Index (ASI) is a widely used clinical tool for assessing addiction severity.
• Opiate/opioid overdose is a significant public health crisis, with many daily fatalities.

Purpose of the Study:

• To introduce the Genetic Addiction Risk Score (GARS) as a novel genetic test for addiction risk.
• To evaluate the correlation between GARS and the Addiction Severity Index (ASI) for alcohol and drug dependency.
• To explore the utility of GARS in personalized addiction treatment and clinical decision-making.

Main Methods:

• Development of the Genetic Addiction Risk Score (GARS) based on ten reward gene risk variants.
• Comparison of GARS with the Addiction Severity Index (ASI) in unpublished work.
• Analysis of GARS as a predictor of alcohol and drug dependency severity.

Main Results:

• GARS significantly predicted the severity of both alcohol and drug dependency when compared to the ASI.
• GARS is the only known gene panel reflecting the Brain Reward Cascade (BRC) correlated with ASI-MV scores.
• The study suggests GARS can aid in risk assessment and treatment planning.

Conclusions:

• GARS offers a non-invasive genetic test to improve clinical interactions and decision-making in addiction treatment.
• Genomic testing with GARS can assist in determining appropriate therapies, level of care, and treatment duration.
• Knowledge of polymorphic associations can help personalize pharmacogenetic monitoring for better clinical outcomes.